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a b s t r a c t
Vitamin E is likely the most important antioxidant in the human diet and α-tocopherol is the most active
isomer. α-Tocopherol exhibits anti-oxidative capacity in vitro, and inhibits oxidation of LDL. Beside this,
α-tocopherol shows anti-inﬂammatory activity and modulates expression of proteins involved in uptake,
transport and degradation of tocopherols, as well as the uptake, storage and export of lipids such as cholesterol.
Despite promising anti-atherogenic features in vitro, vitamin E failed to be atheroprotective in clinical trials in
humans. Recent studies highlight the importance of long-chain metabolites of α-tocopherol, which are formed
as catabolic intermediate products in the liver and occur in human plasma. These metabolites modulate
inﬂammatory processes and macrophage foam cell formation via mechanisms different than that of their
metabolic precursor α-tocopherol and at lower concentrations. Here we summarize the controversial role of
vitamin E as a preventive agent against atherosclerosis and point the attention to recent ﬁndings that highlight
a role of these long-chain metabolites of vitamin E as a proposed new class of regulatory metabolites. We
speculate that the metabolites contribute to physiological as well as pathophysiological processes.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).
Contents
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495
Pathogenesis of atherosclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496
Effects of α-Tocopherol on atherogenic processes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496
α-Tocopherol metabolites and their bioactivity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498
Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
Sources and Funding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500
Disclosures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500
Introduction
Atherosclerosis is a progressive inﬂammatory disease charac-
terized by excessive deposition of cholesterol in the arterial wall.
Despite intensive therapeutic treatment opportunities the athero-
sclerotic complications are still the leading cause of death in
Western industrialized countries.
Leonardo da Vinci (1452–1519) was probably the ﬁrst who
described the macroscopic changes of atherosclerosis, when he
illustrated the lesions in arteries obtained from an elderly man
at autopsy. His visionary idea was that the pathological thickening
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of the arterial wall was due to ‘excessive nourishment’ from the
blood. Many decades later da Vinci's observation was studied in
more detail by Carl von Rokitansky (1852) and Rudolf L. K. Virchow
(1821–1902). In 1856 Virchow proposed that injury of the endothe-
lium may initiate the disease process of atherosclerosis. Based on
this idea, Russell Ross (1929–1999) and John A. Glomset came up in
1973 with the ‘response-to-injury’ hypothesis which is still gener-
ally accepted today in the form of the more generalized concept of
endothelial dysfunction as the initial cause of atherosclerosis.
The pioneering work of Virchow and Nikolai N. Anitschkow
(1885–1964) provided ﬁrst evidence for the importance of the
deposition of lipids from the blood, in particular cholesterol, in
the arterial wall. Their ﬁndings formed the basis for the lipid
hypothesis which connects plasma cholesterol levels to the devel-
opment of the disease. In 1951, G. Lyman Duff (1904–1956) and
Gardner C. McMillan (1918–2004) formulated the lipid hypothesis
in its modern form, which is, despite controversial discussions, still
widely accepted today. Since the discovery of the importance of the
cholesterol contained in low-density lipoprotein (LDL2) particles for
the pathogenesis of atherosclerosis, the concept of endothelial
dysfunction has become tightly linked to the lipid hypothesis.
Almost 30 years ago the concept originated from work by Daniel
Steinberg and Joseph L. Witztum that oxidative stress and the
oxidation of LDL particles might contribute to atherosclerosis. The
idea came up from the observation that the incubation of macro-
phages with oxidized LDL (oxLDL3) but not with native LDL led to the
intracellular accumulation of cholesteryl esters. The idea that oxidative
stress is involved in atherogenesis gained much attention and created
tremendous excitement to look for oxLDL in vivo as well as for
different kinds of oxidized lipid species within the particle. Since
oxLDL appears in human plasma as well as within the arterial wall it
was even a small step to the idea that supplementation with
antioxidants may prevent atherosclerosis by inhibiting the formation
of oxLDL. This hypothesis appeared to be on solid ground due to
epidemiological evidence and the success in several animal studies
using a variety of antioxidants. The euphoria of initial success led to
clinical trials to validate the hypothesis and natural antioxidants were
of particular interest as the expectation was that these natural
compounds would have less undesirable effects. Accordingly a number
of clinical trials were performed using, for example, vitamin E, which
surprisingly have not been overwhelmingly supportive of the hypoth-
esis. An overview on the controversial ﬁndings for vitamin E obtained
from clinical trials is given in Fig. 1.
In this review, we want to summarize the controversial role of
vitamin E as a preventive agent against atherosclerosis and to
point the attention to recent ﬁndings by our group that highlight a
role of long-chain metabolites of vitamin E as a proposed new
class of regulatory metabolites and to their potential contribution
to atherosclerotic processes.
Pathogenesis of atherosclerosis
The endothelium covering the arterial walls comprises a physiolo-
gical and selective barrier, the so-called intima, between blood and the
inner layer of the arterial wall. This so-called media is comprised by
contractile smooth muscle cells. Pathophysiological stimuli cause
endothelial dysfunction triggering inﬂammatory processes in the
vascular wall which result under chronic conditions in extensive
morphological changes characterized by intimal thickening, deposition
of cholesterol and ﬁbrotic material, loss of elasticity, reduction of
vascular lumen, and widening of the vessel diameter [1]. Endothelial
dysfunction is thought to be caused by exogenous stimuli, such as
environmental factors (e.g., toxicants such as dioxins, PCBs, and
pesticides), unhealthy lifestyle (e.g., smoking and physical inactivity)
and dietary habits (e.g., high intake of saturated fat). The impact of
exogenous factors depends on endogenous local and systemic condi-
tions. Local factors are vessel-associated junctions, bifurcations and
curvatures which are responsible for increased shear stress caused by
turbulences of the blood stream in these areas, which are thus
predestinated for the formation of atherosclerotic lesions [2]. Pro-
atherogenic systemic factors are determined either genetically or
pathophysiologically, for example, in case of increased LDL and
triglyceride plasma levels [3,4] as well as inﬂammatory conditions
[5]. The process of atherosclerosis is outlined and explained in more
detail in Fig. 2.
A key event of atherogenesis is the loss of the selective
endothelial barrier by endothelial dysfunction which allows, for
example, LDL to enter the arterial wall. Once inside the vessel wall,
LDL particles become prone to oxidation. The oxidized particles
cause damage to the tissue thus triggering a cascade of immune
and inﬂammatory responses. In addition, macrophages, the pha-
gocytic cells of the immune system, are recruited to the affected
tissue sites to clear the oxLDL particles. As a consequence oxidized
lipids and particularly cholesterol accumulate within the macro-
phages as these cells are not able to process the oxLDL completely.
This causes transformation of the cells into so-called foam cells
and ultimately cell death as the excessive accumulation of intra-
cellular lipids is cytotoxic. Death of macrophage foam cells results
over time in the extracellular deposition of cholesterol in the
arterial wall and the formation of an atheroma. The process of
atherosclerosis is outlined and explained in more detail in Fig. 2.
Thus, vitamin E was considered as an anti-atherogenic agent
for a long time as prevention of LDL oxidation by providing
increased levels of antioxidants would prevent the formation of
macrophage foam cells and atheroma, and would dampen the
immune and inﬂammatory response.
Effects of α-Tocopherol on atherogenic processes
Vitamin E is likely the most important lipid antioxidant in the
human diet. The term vitamin E comprises a group of eight abundant
isomers (α-, β-, γ-, δ-tocopherol and -tocotrienol), that differ by their
methylation patterns of the hydroxychromanol ring and saturation of
the side-chain. Many in vitro studies have been performed with
Nomenclature
α-130-OH α-130-(6-hydroxy-2,5,7,8,-tetramethylchroman-
2-yl)-2,6,10-trimethyl-tridecanol
α-130-COOH α-130-(6-hydroxy-2,5,7,8,-tetramethylchroman-
2-yl)-2,6,10-trimethyl-tridecanoic acid
α-CEHC α-carboxyethyl-hydroxychroman
α-LCM α-tocopherol long-chain metabolites
α-SCM α-tocopherol short-chain metabolites
α-TOH α-tocopherol
COX cyclooxygenase
CYP3A4 cytochrome P450, subfamily IIIA, polypeptide 4
CYP4F2 cytochrome P450, subfamily IVF, polypeptide 2
LDL low density lipoprotein
oxLDL oxidized low density lipoprotein
2 LDL, low density lipoprotein.
3 oxLDL, oxidized low density lipoprotein.
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α-tocopherol (α-TOH4) which is the most active isomer within the
group of vitamin E [6]. α-Tocopherol exhibits anti-oxidative capacity
in vitro [7], and it has been shown to particularly inhibit, for example,
the oxidation of LDL. Beside this, α-TOH shows anti-inﬂammatory
features by, for example, inhibiting cyclooxygenase (COX5) 2. Next to
its anti-inﬂammatory and anti-oxidative properties, the vitamin E
Fig. 1. Effects of α-TOH in vivo. Many in vitro investigations (A) focused on the identiﬁcation of α-TOH-regulated signaling pathways and its effects on inﬂammation, lipid
homeostasis, atherosclerotic plaque stability as well as xenobiotic metabolism as key processes. Taken together most of the in vitro studies implicated that vitamin E, and
particularly α-TOH, may be used to prevent or cure cardiovascular disease (CVD) and related diseases, such as atherosclerosis. Based on very promising studies in vitro and
with animals several large-scaled human intervention trials were initiated and followed up over years. Unfortunately, the trials revealed controversial results and failed to
demonstrate clear invers relations or positive effects of α-TOH supplementation with respect to the prevention of cardiovascular complications [21] (B). Further, α-TOH serum
levels did not correlate with cardiovascular outcomes in different cohorts. Although some studies reported promising ﬁndings, such as the ‘Nurses’ Health Study (NHS) [22]
including 87,000 volunteers in which vitamin E supplementation was associated with a lower risk of major coronary disease, other large-scale studies, such as the Heart
Outcomes Prevention Evaluation (HOPE) study [23], the SU.VI.MAX study [24], the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) study
[25] did not conﬁrm that vitamin E intake correlates negatively with cardiovascular outcomes. Other studies revealed also contrary results depending on the time of follow-
up and the cardiovascular parameter investigated or they showed unclear results (for example, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) [26–
30], the Physicians' Health Study [31], the Health Professionals Follow-up Study (HPFS) [32,33]). In a recent meta-analysis Ye et al. also found no signiﬁcant inverse
correlation for CVD and cardiovascular mortality under vitamin E [34]. Reasons for the poor outcomes of clinical trials are hardly to deﬁne. Beside a general failure of vitamin
E, other reasons may explain the lack of any cardio-preventive effect. Likely the selection of volunteers, the sizes of cohorts, doses and duration of supplementation or rather
the application form of vitamin E with respect to its bioavailability, the food questionnaires and variability of food intake may explain the ﬁndings. Furthermore, it cannot be
excluded that the interaction of vitamin E with other food ingredients contributes to the lack of its cardio-preventive activity. From a technical point of view, it cannot be
excluded that vitamin E in stored sample is chemically modiﬁed or degraded so that frozen biological samples are not completely comparable to fresh samples. Another
important point refers to the fact that most of the intervention trials concentrated on secondary prevention in patients with already existing CVD. It has been suggested that
vitamin E supplementation may be more effectively for inhibiting the early stages of atherosclerosis [35] and should be considered for primary prevention, as recently
supported by Meydani et al. emphasizing the beneﬁcial effects of long-term vitamin E supplementation in Ldlr/ mice under healthy life-style conditions, such as low fat
diet [36]. However, this hypothesis has not yet been conﬁrmed. In summary (C), there is no clear evidence that supplementation with vitamin E correlates inversely with CVD
incidence. Meta-analyses of observation studies suggest that vitamin E intake may prevent CVD and cardiovascular events [37–39]. Knekt et al. performed a pooled analysis
of observation studies with dietary vitamin E intake and supplementation in separate arms and found a signiﬁcant inverse correlation of intake and CVD events only in the
supplementation group [40]. Apart from that meta-analysis of intervention studies provide evidence that supplementation with vitamin E does not reduce CVD incidence
[38,41–43]. There are several drawbacks of meta-analysis that should be considered while interpreting these results, such as combination of heterogeneous data sets
(regarding quality, statistics and focus within the topic), publication bias as well as criteria for inclusion and exclusion of the meta-analysis. However, it cannot yet be
excluded that vitamin E intake is protective at least in some groups of humans against CVD as primary prevention. It is also important to remind that Miller et al. focused in
their meta-analysis on some intervention studies, which provided evidence for an increase in all-cause mortality after supplementation with high doses of vitamin E [44].
These ﬁndings in humans raise the question whether α-TOH in vivo exhibits modes of action different from those found in vitro. Possible explanations for the inability of
vitamin E to prevent CVD and its complications in clinical trials in humans have been outlined above and are summarized in (D). Abbreviations and references: Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) [26–30], Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) [45], Austria [46], Cambridge Heart
Antioxidant Study (CHAOS) [47], Cancer Prevention Study II (CPS-II) [48], Costa Rica [49], Czech Republic [50], Eastern Finland Heart Surveys [51], Epidemiologic Study of
Cardiovascular Risk Indicators (EPOZ Study) [52], Established Populations for Epidemiologic Studies of the Elderly (EPESE) [53], Finnish Mobile Clinic Examination Survey
(FMC) [54], Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) [25], HDL-Atherosclerosis Treatment Study (HATS) [55], Health Check-up
Program (CHEP) [56], Heart Outcomes Prevention Evaluation Study (HOPE) [23], HOPE-The Ongoing Outcomes [HOPE-TOO] [57], Iowa Women's Health Study (IWHS) [58],
Japan [59], Lixian dysplasia trial (LIXIAN-2) [60,61], Medical Research Council/British Heart Foundation (MRC/BHF) [62], Multinational MONItoring of trends and
determinants in CArdiovascular disease (MONICA) [63], Noninstitutionalized Massachusetts Residents (NMR) [64], Physicians' Health Study (PHS) [31], Physicians' Health
Study II (PHS-II) [65], Rotterdam Study [66], Scotland and UK [67], Scottish Heart Health Study (SHHS) [68], Secondary prevention with antioxidants of cardiovascular disease
in endstage renal disease (SPACE) [69], Shanghai Survey [70], South African [71], South of India [72], Supplémentation en Vitamines et Minéraux Antioxydants (SU.VI.MAX)
[24], Tehran [73], The Health Professionals Follow-up Study (HPFS) [32,33], The Multiple Risk Factor Intervention Trial (MRFIT) [74], The Nurses' Health Study (NHS) [22], The
Primary Prevention Project (PPP) [75], The Zutphen Study (ZS) [76], Tunisian [77], UK [78], Women's Antioxidant Cardiovascular Study (WACS) [79], Women's Health Study
(WHS) [80], 9 countries [81]. The name of countries/cities refers to the countries/cities in which the studies have been performed, if no name for the studies is available.
4 α-TOH, α-tocopherol. 5 COX, cyclooxygenase.
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isomers may have a variety of further independent properties, namely
the modulation of gene expression, particularly that of genes encoding
proteins involved in signaling but also the uptake, transport and
degradation of tocopherols, as well as the uptake of lipoproteins and
the storage and export of lipids such as cholesterol. The in vitro and
ex vivo effects of α-tocopherol on cellular processes are depicted in
Fig. 3.
α-Tocopherol metabolites and their bioactivity
Metabolic degradation of α-TOH takes place almost exclusively in
the liver. Beside metabolites resulting from oxidation of the chroman
moiety, hepatic metabolism of α-TOH involves CYP3A46-dependent
ω-hydroxylation and α-oxidation, which results in the formation
of the α-tocopherol long-chain metabolites (α-LCM7) α-130-OH8
(130-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-trimethyl-
tridecanol) and α-130-COOH9 (130-(6-hydroxy-2,5,7,8,-tetramethyl-
chroman-2-yl)-2,6,10-trimethyl-tridecanoic acid), and further steps
of β-oxidation, which results in the formation of middle- and short-
chain metabolites (α-SCM10) with the catabolic end-product
α-carboxyethyl-hydroxychroman (α-CEHC11), respectively [8–10].
The short-chain metabolites are excreted via urine and are often
used as a marker for α-TOH supply [11]. Other tocopherols, such as
γ- and δ-tocopherol, are almost quantitatively degraded and excreted
via the urine as the corresponding γ- and δ-CEHCs. The hepatic
metabolism of α-TOH is illustrated in Fig. 4.
Regulatory activity is not restricted to α-TOH as its short-chain
metabolite α-CEHC also exhibits bioactivity. It has been shown that α-
CEHC is anti-proliferative [12], anti-inﬂammatory [13], and anti-
oxidative [14], and inhibits oxLDL formation [15] and protein kinase
C (PKC12) signaling [16]. Recently, researchers focused also on inves-
tigating the cellular effects of the α-LCM as α-130-COOH was detected
in human serum, a ﬁnding providing clear evidence for its systemic
bioavailability. Until now, only a few cellular effects of the α-LCM
have been described, such as pro-apoptotic, anti-proliferative and
anti-inﬂammatory features [17–20], which are highlighted in Fig. 4.
Fig. 2. Key events of atherogenesis. Atherosclerosis is a complex and progressive inﬂammatory disease characterized by extensive morphological changes of the vascular
wall. The arterial wall is composed of the intima, formed by endothelial cells (EC), the media, comprised of smooth muscle cells (SMC), and the adventitia, made of ﬁbroblasts.
The intermediate layers of the arterial vessel are the lamina elastica interna, connecting the intima with the media, and the lamina elastica externa, the connection between
the media and the adventitia. Key changes of the vascular wall during the progression of atherosclerosis are intimal thickening, extensive extracellular deposition of
cholesterol and ﬁbrotic material, loss of elasticity, reduction of the vascular lumen and widening of the arterial diameter [1]. Endothelial dysfunction is caused by exogenous
and endogenous noxes and is the initial event in atherosclerosis. The dysfunction of the endothelium is accompanied by up-regulation of adhesion molecules in EC, which
promote attachment and recruitment of T-lymphocytes and monocytes from the blood (I) and initiate immigration of monocytes into the subendothelial area of the vessel
wall (IIa). Migration of monocytes, T-lymphocytes and SMC from the media (IIb) ﬁnally results in intimal thickening and ﬁbrosis. Following migration of monocytes through
the intima, differentiation of these cells into macrophages occurs (III). Macrophages as the phagocytic cells of the immune system play a pivotal role in the progression of
atherosclerosis. They actively engage by taking up lipids from oxLDL in a non-controlled manner, by storing large amounts of cholesteryl esters, and by mobilizing cholesterol
for reverse cholesterol transport [82,83]. Macrophages also orchestrate the inﬂammatory process, are responsible for the immigration of SMC from the media by releasing
chemotactic molecules and proteases, and modulate the ﬁbrotic process. LDL particles diffuse from the blood into the subendothelial space as a consequence of the loss of the
endothelial barrier during endothelial dysfunction (IV). In the arterial wall the lipids and LDL are subjected to oxidation and enzymatic modiﬁcation. The resulting oxLDL is
taken up by macrophages (V) via scavenger receptors and phagocytosis in uncontrolled fashion [84]. Recent studies have also highlighted the intra-plaque proliferation of
macrophages in the lipid-rich stage of atherosclerotic plaque development (VI) [85]. Accumulation and uptake of oxLDL by macrophages triggers the secretion of chemotactic
molecules [86], which promote the migration of SMC from the media into the subendothelial tissue. The intimal SMC lose their ability to contract, proliferate and synthesize
extracellular matrix which results in ﬁbrosis as part of the plaque development. The deposition of the extracellular matrix leads to further accumulation of oxLDL and lipids,
in particular cholesterol and cholesteryl esters. The uptake of oxLDL via scavenger receptors is not subjected to negative feedback regulation, thus resulting in excessive
intracellular lipid accumulation and formation of macrophage foam cells (VII) [87], as well as the release of chemotactic mediators. During further progression of
atherosclerosis, fatty streaks are formed and the thickening of the vascular wall progresses through the ongoing deposition of extracellular lipids and proliferation of intimal
SMC, and the accompanied synthesis of extracellular matrix proteins. Over many years these processes together form the characteristic necrotic lipid core covered and
stabilized by a ﬁbrotic cap (VIII). The stability of the atherosclerotic plaque is deﬁned by the amount of accumulated lipids and also by the amount and quality of the
extracellular matrix of the ﬁbrotic cap; the progressing accumulation of lipids is often accompanied by reduced stability of the ﬁbrotic cap (IX). Weakening of the cap may
ﬁnally result in rupturing of the plaque, particularly in areas rich in macrophages as these cells produce a broad range of proteases that degrade the extracellular matrix of
the ﬁbrotic cap [88,89]. Plaque rupture causes thrombus formation (X) via the activation of the coagulation cascade [87]. Thrombi may occlude the artery at the site of plaque
rupture or may ﬂow through the blood stream and occlude downstream arteries that have a smaller lumen. In some cases, thrombi at the plaque site are reorganized and
integrated into the plaque. This ﬁnally leads to the formation of the so-called complicated plaque (not shown).
6 CYP3A4, cytochrome P450, subfamily IIIA, polypeptide 4.
7 α-LCM, α-tocopherol long-chain metabolite(s).
8 α-130-OH, α-130-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-tri-
methyl-tridecanol.
9 α-130-COOH, α-130-(6-hydroxy-2,5,7,8,-tetramethylchroman-2-yl)-2,6,10-tri-
methyl-tridecanoic acid.
10 α-SCM, α-tocopherol short-chain metabolite(s).
11 α-CEHC, α-carboxyethyl-hydroxychroman.
12 PKC, protein kinase C.
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A recent study by our group showed that α-LCM also affect macro-
phage foam cell formation by regulating uptake of oxLDL by macro-
phages via down-regulation of its phagocytic uptake (Fig. 4) [17]. A key
ﬁnding of our study was that bioactivity of the α-LCMs occurs at much
lower concentrations and with mechanisms distinct from those of
their metabolic precursor α-TOH.
Perspective
The ﬁndings obtained from clinical trials with humans raise the
question whether vitamin E in vivo exhibits modes of action different
from those found in vitro. Recent studies shed new light on mechan-
istic aspects of α-TOH function, which appear to be complicated by
Fig. 3. Atherosclerosis-relevant in vitro and ex vivo effects of α-tocopherol. Due to its function as an antioxidant, vitamin E was considered to interfere with key events in
atherogenesis. To gain better insights into the contribution of vitamin E to the molecular processes underlying the hallmarks of atherosclerosis much effort was spend on
in vitro and ex vivo experiments as well as studies involving animal models. As the complex pathogenesis of atherosclerosis involves several different cell types, the ﬁgure is
divided according to the cells of interest (EC, SMC, monocytes and macrophages, hepatocytes) as well as non-cellular, plaque-speciﬁc processes and categories such as lipid
homeostasis, signaling, inﬂammation, plaque stability and xenobiotic metabolism which are used to reﬂect the hallmarks of atherosclerosis. Endothelial cells surface the
arterial wall and their dysfunction is the initial step of atherogenesis. α-Tocopherol reduces the stimulus-induced expression of adhesion molecules, such as vascular cell
adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and E-selectin [90–92], and decreases thereby the adhesion [92] and immigration of leukocytes
[93] onto the endothelium or into the arterial wall, respectively. α-Tocopherol makes it easier for EC to deal with oxidative stress, such as H2O2-induced lipid peroxidation [7],
due to higher catalase expression [94], increased H2O2 degradation activity, and higher intracellular GSH levels [13]. Thus, apoptosis of EC induced by oxidative stress is
reduced [95]. Beside reducing the release of inﬂammatory cytokines, such as interleukin (IL) 8 [96], in response to external stimuli, α-TOH interferes with cellular signaling by
inhibiting, for example, PKC [97], activate nuclear factor κB (NFκB) [98] or binding of peroxisome proliferator-activated receptor γ (PPARγ) to its regulatory DNA elements
[94]. Lipid homeostasis of SMC is also affected by α-TOH, for example by down-regulation of the scavenger receptor CD36 leading to reduced uptake of oxLDL [99].
α-Tocopherol inhibits migration [100] and proliferation of SMC by inhibiting PKC [101], and prevents 7-ketocholesterol-induced apoptosis [102]. Plaque stability is modulated
by connective tissue growth factor (CTGF), which stimulates the synthesis of extracellular matrix. This factor is induced by α-TOH in SMC [103], suggesting that α-TOH
contributes to plaque stability by inducing ﬁbrotic processes. Several signaling cascades in SMC are also modulated by α-TOH, namely PKC [104,105], extracellular signal-
regulated kinase (ERK) [106], protein kinase B (PK/AKT) and protein phosphatase 2A [107]. Monocytes migrate in the arterial wall, differentiate into macrophages and
transform to foam cells under atherogenic conditions. α-Tocopherol reduces adhesion and migration of leukocytes by down-regulating expression of CD11b [93] and very late
antigen-4 (VLA-4) [92,108]. Macrophage foam cell formation is prevented by reducing the expression of scavenger receptors CD36 [109,110] and A [111]. On the other hand,
foam cell formation is triggered by the down-regulation of the lipid exporters ATP-binding cassette transporter (ABC) A1 and G1 [110]. Furthermore, the inﬂammatory
response of macrophages to stimuli such as lipopolysaccharide (LPS) is dampened. The diminished induction of COX2 and inducible nitric oxide synthase (iNOS) by α-TOH
results in a reduced release of prostaglandin E2 (PGE2) and nitric oxide [112,113]. The release of pro-inﬂammatory cytokines such as IL-1b, IL-6, tumor necrosis factor α
(TNFα), and interferon γ (IFNγ) is also reduced [113]. Similar to SMC, 7-ketocholesterol-induced apoptosis is reduced by α-TOH in macrophages [114,115]. Signaling pathways,
such as NFκB [108] and oxLDL or lipid-free high density lipoprotein induced liver X receptor α (LXRα) activity, are also inhibited by α-TOH [110]. The liver is the major organ
for cholesterol biosynthesis and metabolism of lipoproteins, xenobiotics and α-TOH. In liver cells α-TOH down-regulates expression of CD36 [116,117] and the LDL receptor
[118], as well as expression of enzymes involved in cholesterol biosynthesis, such as HMG-CoA reductase and HMG-CoA synthase [118]. In contrast, expression of cytochrome
P450 subfamily 27A polypeptide 1 (CYP27A1), and thus synthesis of 27-hydroxycholesterol, is induced by α-TOH [119]. Similar to the situation in macrophages, activation of
NFκB and expression of iNOS in response to stimuli is reduced by α-TOH [120]. α-Tocopherol also induces CYP3A11 to levels which might interfere with drug metabolism
[121]. In addition to the effects of α-TOH on the different cell types involved in atherogenesis, α-TOH improves plaque stability in hyperlipidemic rabbits. Treatment of the
animals with α-TOH increased the number of plaques with thicker, stabilizing ﬁbrotic caps and reduced necrotic lipid core areas as well as reduced number of ruptured
plaques [122]. Formation of oxLDL was also blocked by α-TOH [123]. Several studies using animals such as hypercholesterolemic rabbits or mice suggest that vitamin E
inhibits atherogenesis in early [124] or advanced stages by its antioxidant capacity [125] or gene regulatory potential via signal transduction cascades and on adhesion
molecules [126,127]. While high dose supplementation of vitamin E can improve myocardial tolerance to ischemia and reperfusion [128], Keaney et al. found that low dose
α-TOH improves and high dose worsens endothelial vasodilatory function in cholesterol-fed rabbits [129]. Under extreme conditions, such as pronounced elevation in
systemic oxidative stress due to hyperlipidaemia and obesity, vitamin E seems to be not cardioprotective [130].
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α-LCM circulating in the blood. We speculate that the α-LCM
represent a new class of regulatory metabolites and propose that
unraveling the molecular modes of action of the α-LCM and identify-
ing the key players involved in their signaling may provide new
fundamental insights into the biology and mode of function of vitamin
E. Further studies are therefore required to elucidate the physiological
role of the α-LCM and their contribution to disease processes, such as
atherosclerosis. We also hypothesize that the discrepancy between the
results obtained in vitro and in vivo in humans may be due to
the physiologic metabolism of α-TOH and the formation of α-LCM in
the liver and their release into circulation.
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